What Liraglutide is
Liraglutide is a GLP-1 receptor agonist with established clinical use in metabolic disease contexts.
Liraglutide is grouped under Fat Loss + GLP-1s / Approved / Clinical on PeptideFactCheck because it is an older GLP-1 benchmark that helps explain how the category evolved before semaglutide and tirzepatide.
The useful starting point is to separate the molecule itself from the internet story around it. It was one of the major GLP-1 drugs before semaglutide dominated the conversation.
Why people keep looking it up
People associate liraglutide with appetite control, weight loss, and diabetes treatment.
Liraglutide activates GLP-1 receptors involved in appetite and glucose regulation.
Liraglutide tends to stay in the conversation because it touches a familiar public theme: glp-1 receptor, glucose, and appetite signaling. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Approved use is source-backed, but it should not be blurred with unapproved peptide products.
Human trials and official labeling support approved uses.
Mechanism follows GLP-1 receptor pharmacology and incretin biology.
Why this page carries the current tier: Approved drug with human clinical evidence and official labeling.
The current seed trail for Liraglutide is pulling from 1 labels source, 1 regulatory source, and 1 literature source.
Safety, limits, and regulatory context
Risk framing should follow current official labeling and should not be generalized to non-approved products.
FDA-approved liraglutide products exist for specific indications.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Liraglutide. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Liraglutide is CID 16134956. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 16134956
- Formula
- C172H265N43O51
- Molecular weight
- 3751
- InChIKey
- YSDQQAXHVYUZIW-QCIJIYAXSA-N
Matched synonyms include Liraglutide, 204656-20-2, NN2211, Saxenda, victoza, Liraglutida, NN-2211, Liraglutidum.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Liraglutide returns 509 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Liraglutide returns 5626 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- Liraglutide
- Generic names
- LIRAGLUTIDE
- Routes
- SUBCUTANEOUS
- Application numbers
- ANDA215421
Indications and usage. 1 INDICATIONS AND USAGE Liraglutide injection is indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus Limitations of Use: Liraglutide injection contains liraglutide. Coadministration with other liraglutide-containing products is not recommended. Liraglutide injection is a glucagon-like peptide-1 (GLP-1) recept...
Warnings and cautions. 5 WARNINGS AND PRECAUTIONS Acute Pancreatitis : Has been observed in patients treated with GLP-1 receptor agonists, including liraglutide injection. Discontinue if pancreatitis is suspected. ( 5.2 ) Never Share a liraglutide injection Pen Between Patients, even if the needle is changed. ( 5.3 ) Hypoglycemia : Adult patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, includi...
Contraindications. 4 CONTRAINDICATIONS Liraglutide injection is contraindicated in patients with a: personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions ( 5.1 )] . serious hypersensitivity reaction to liraglutide or to any of the excipients in liraglutide injection. Serious hypersensitivity reactions including anaphylactic...
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.